Results 1 to 10 of about 580 (99)

Real-world evidence on tagraxofusp for blastic plasmacytoid dendritic cell neoplasm – collected cases from a single center and case reports [PDF]

Frontiers in Oncology
IntroductionBlastic plasmacytoid dendritic cell neoplasia (BPDCN) is a rare, aggressive hematologic malignancy. Until recently, the only curative treatment consisted of intensive chemotherapy, followed by hematopoietic cell transplantation (HCT) in ...
Claudia Lengerke, Lucas Mix, Wichard Vogel   +2 more
exaly   +4 more sources

Longer survival and favorable healthcare resource utilization of tagraxofusp versus venetoclax in patients with blastic plasmacytoid dendritic cell neoplasm: results of a real-world analysis [PDF]

Frontiers in Oncology
BackgroundTagraxofusp is a first-in-class CD123-targeted therapy approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN). Although venetoclax is not approved for BPDCN, limited use has been reported.
Anthony S. Stein, Guru Subramanian Guru Murthy, Pankit Vachhani, Sunil Iyer, Deborah Goldschmidt, Yipeng Gao, John Katsetos, Corey Pelletier, Tibor Kovacsovics   +8 more
doaj   +2 more sources

Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base [PDF]

Leukemia Research Reports
BPDCN is an aggressive myeloid malignancy characterized by unique expression of CD123, CD4, CD56, CD303, CD304, TCL1 and TCF4. The development of tagraxofusp, a CD123-directed cytotoxin, has revolutionized BPDCN treatment, especially for patients unfit ...
Nathan M. Krah, Rasmus Hoeg, Paul J. Shami, Shannon E. Elf, Lauren E. Lee, Naveen Pemmaraju, Ami B. Patel   +6 more
doaj   +2 more sources

Sustained response to minimal-dose tagraxofusp in a patient with BPDCN and advanced chronic kidney disease [PDF]

Annals of Hematology
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an extremely rare hematologic malignancy with an aggressive course and poor prognosis. Treatment remains challenging particularly in patients who are ineligible for stem cell transplantation due to ...
Christina Brummer, Katja Evert, Felix Keil, Jakob Schmidt, Matthias Grube, Wolfgang Herr, Markus Radsak, Stephanie Mayer   +7 more
doaj   +2 more sources

Tagraxofusp in adult blastic plasmacytoid dendritic cell neoplasm: clinical trials and real-world outcomes: a systematic review [PDF]

Frontiers in Immunology
BackgroundBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy. Tagraxofusp, a CD123-directed cytotoxin, was approved based on phase I/II data, and subsequent studies have expanded evidence across trial and ...
Bassam Muthanna, Aadhila Abbas Manthiri, Leen Haj Saleh, Abdulrahman F. Al-Mashdali, Shehab F. Mohamed   +4 more
doaj   +2 more sources

Foot gangrene following Tagraxofusp treatment for blastic plasmacytoid dendritic cell neoplasm: Case report

EJHaem, 2022
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy. It is associated with poor prognosis and heterogenous presentation. The CD123‐directed cytotoxin, Tagraxofusp, is a targeted therapy for BPDCN. Here, we
Ibrahim Al Nabhani, Jad Sibai
exaly   +2 more sources

Tagraxofusp, a CD123-targeted therapy, for chronic myelomonocytic leukemia: final results of a phase 1/2 study [PDF]

Blood Neoplasia
: Chronic myelomonocytic leukemia (CMML) is an aggressive hematologic neoplasm characterized by an expansion of CD123+ monocytes and plasmacytoid dendritic cells (pDCs).
Mrinal M. Patnaik, Haris Ali, Eunice S. Wang, Abdulraheem Yacoub, James M. Foran, Vikas Gupta, Gary J. Schiller, Don Ambrose Stevens, Moshe Talpaz, Sarah Wall, Terra L. Lasho, Abhishek A. Mangaonkar, Talha Badar, Ross Lindsay, Antonio Galleu, Ira Gupta, Naveen Pemmaraju, Guillermo Garcia-Manero   +17 more
doaj   +2 more sources

Clinically approved immunotoxins targeting hematological cancers: “the best of both worlds” [PDF]

Frontiers in Pharmacology
Hematological malignancies contribute significantly to the overall cancer burden. Certain subtypes, such as hairy cell leukemia (HCL), are chronic and characterized by residual disease after first-line therapy, while others, such as blastic plasmacytoid ...
Yasmine Rashad, Yasmine Rashad, Eckhard U. Alt, Reza Izadpanah, Xuebin Qin, Xuebin Qin, Stephen E. Braun, Stephen E. Braun, Stephen E. Braun   +8 more
doaj   +2 more sources

First-line tagraxofusp leads to durable responses and prolonged survival in adults with blastic plasmacytoid dendritic cell neoplasm regardless of fitness level [PDF]

Haematologica
Not available.
Naveen Pemmaraju, Marco Herling, Kendra L. Sweet, Anthony S. Stein, Sumithira Vasu, Todd L. Rosenblat, David A. Rizzieri, Cristina Papayannidis, Eunice S. Wang, Marina Konopleva, Michael Zuurman, Alessandra Tosolini, Muzaffar Qazilbash, Andrew A. Lane   +13 more
doaj   +2 more sources

Clinical Activity and Tolerability of SL-401 (Tagraxofusp): Recombinant Diphtheria Toxin and Interleukin-3 in Hematologic Malignancies

Biomedicines, 2019
Overcoming the leukemia stem cell resistance to intensive chemotherapy has been an area of extensive research over the last two decades. Advances and greater understanding of the molecular biology of leukemia stem cells are in rapid progress.
Arthur Frankel, Omar Alkharabsheh
exaly   +3 more sources